99 related articles for article (PubMed ID: 15125539)
1. Coinfection with Listeria monocytogenes potentlxtes the response of BALB/c mice against Leishmania major.
Tabbara KS; Al-Azmi AS; Al Salem JA
J Egypt Soc Parasitol; 2004 Apr; 34(1):349-66. PubMed ID: 15125539
[TBL] [Abstract][Full Text] [Related]
2. Control of Leishmania major infection in BALB/c mice by inhibition of early lymphocyte entry into peripheral lymph nodes.
Laskay T; Wittmann I; Diefenbach A; Röllinghoff M; Solbach W
J Immunol; 1997 Feb; 158(3):1246-53. PubMed ID: 9013966
[TBL] [Abstract][Full Text] [Related]
3. Genetically resistant mice lacking interleukin-12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response.
Mattner F; Magram J; Ferrante J; Launois P; Di Padova K; Behin R; Gately MK; Louis JA; Alber G
Eur J Immunol; 1996 Jul; 26(7):1553-9. PubMed ID: 8766560
[TBL] [Abstract][Full Text] [Related]
4. Differential regulation of IL-9-expression after infection with Leishmania major in susceptible and resistant mice.
Gessner A; Blum H; Röllinghoff M
Immunobiology; 1993 Dec; 189(5):419-35. PubMed ID: 8125519
[TBL] [Abstract][Full Text] [Related]
5. Induction of a Th2 population from a polarized Leishmania-specific Th1 population by in vitro culture with IL-4.
Mocci S; Coffman RL
J Immunol; 1995 Apr; 154(8):3779-87. PubMed ID: 7706719
[TBL] [Abstract][Full Text] [Related]
6. Pregnancy impairs resistance of C57BL/6 mice to Leishmania major infection and causes decreased antigen-specific IFN-gamma response and increased production of T helper 2 cytokines.
Krishnan L; Guilbert LJ; Russell AS; Wegmann TG; Mosmann TR; Belosevic M
J Immunol; 1996 Jan; 156(2):644-52. PubMed ID: 8543816
[TBL] [Abstract][Full Text] [Related]
7. Distinct immunological states in murine cutaneous leishmaniasis by immunising with different amounts of antigen: the generation of beneficial, potentially harmful, harmful and potentially extremely harmful states.
Bretscher PA; Ogunremi O; Menon JN
Behring Inst Mitt; 1997 Feb; (98):153-9. PubMed ID: 9382736
[TBL] [Abstract][Full Text] [Related]
8. IFN-gamma modulates the early development of Th1 and Th2 responses in a murine model of cutaneous leishmaniasis.
Scott P
J Immunol; 1991 Nov; 147(9):3149-55. PubMed ID: 1833466
[TBL] [Abstract][Full Text] [Related]
9. Leishmania major: a clone with low virulence for BALB/c mice elicits a Th1 type response and protects against infection with a highly virulent clone.
Li J; Nolan TJ; Farrell JP
Exp Parasitol; 1997 Sep; 87(1):47-57. PubMed ID: 9287957
[TBL] [Abstract][Full Text] [Related]
10. Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis.
Zadeh-Vakili A; Taheri T; Taslimi Y; Doustdari F; Salmanian AH; Rafati S
Vaccine; 2004 May; 22(15-16):1930-40. PubMed ID: 15121305
[TBL] [Abstract][Full Text] [Related]
11. LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile.
Skeiky YA; Kennedy M; Kaufman D; Borges MM; Guderian JA; Scholler JK; Ovendale PJ; Picha KS; Morrissey PJ; Grabstein KH; Campos-Neto A; Reed SG
J Immunol; 1998 Dec; 161(11):6171-9. PubMed ID: 9834103
[TBL] [Abstract][Full Text] [Related]
12. T helper 1 response against Leishmania major in pregnant C57BL/6 mice increases implantation failure and fetal resorptions. Correlation with increased IFN-gamma and TNF and reduced IL-10 production by placental cells.
Krishnan L; Guilbert LJ; Wegmann TG; Belosevic M; Mosmann TR
J Immunol; 1996 Jan; 156(2):653-62. PubMed ID: 8543817
[TBL] [Abstract][Full Text] [Related]
13. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.
Iborra S; Carrión J; Anderson C; Alonso C; Sacks D; Soto M
Infect Immun; 2005 Sep; 73(9):5842-52. PubMed ID: 16113303
[TBL] [Abstract][Full Text] [Related]
14. Regulatory B cells shape the development of Th2 immune responses in BALB/c mice infected with Leishmania major through IL-10 production.
Ronet C; Hauyon-La Torre Y; Revaz-Breton M; Mastelic B; Tacchini-Cottier F; Louis J; Launois P
J Immunol; 2010 Jan; 184(2):886-94. PubMed ID: 19966209
[TBL] [Abstract][Full Text] [Related]
15. IL-12 is required for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis.
Scharton-Kersten T; Afonso LC; Wysocka M; Trinchieri G; Scott P
J Immunol; 1995 May; 154(10):5320-30. PubMed ID: 7730635
[TBL] [Abstract][Full Text] [Related]
16. Acute cysticercosis favours rapid and more severe lesions caused by Leishmania major and Leishmania mexicana infection, a role for alternatively activated macrophages.
Rodríguez-Sosa M; Rivera-Montoya I; Espinoza A; Romero-Grijalva M; López-Flores R; González J; Terrazas LI
Cell Immunol; 2006 Aug; 242(2):61-71. PubMed ID: 17118349
[TBL] [Abstract][Full Text] [Related]
17. Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis.
Webb JR; Kaufmann D; Campos-Neto A; Reed SG
J Immunol; 1996 Dec; 157(11):5034-41. PubMed ID: 8943412
[TBL] [Abstract][Full Text] [Related]
18. The IL-4 rapidly produced in BALB/c mice after infection with Leishmania major down-regulates IL-12 receptor beta 2-chain expression on CD4+ T cells resulting in a state of unresponsiveness to IL-12.
Himmelrich H; Parra-Lopez C; Tacchini-Cottier F; Louis JA; Launois P
J Immunol; 1998 Dec; 161(11):6156-63. PubMed ID: 9834101
[TBL] [Abstract][Full Text] [Related]
19. Oral immunization using live Lactococcus lactis co-expressing LACK and IL-12 protects BALB/c mice against Leishmania major infection.
Hugentobler F; Di Roberto RB; Gillard J; Cousineau B
Vaccine; 2012 Aug; 30(39):5726-32. PubMed ID: 22814408
[TBL] [Abstract][Full Text] [Related]
20. Phlebotomus papatasi sand fly salivary gland lysate down-regulates a Th1, but up-regulates a Th2, response in mice infected with Leishmania major.
Mbow ML; Bleyenberg JA; Hall LR; Titus RG
J Immunol; 1998 Nov; 161(10):5571-7. PubMed ID: 9820534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
